PCMA sues to exempt PBMs from Illinois drug law
The drug middlemen lobby has had a busy week. It’s the second major lawsuit the PCMA has filed against a state law reforming the PBM industry since Monday.
OhioHealth settles antitrust suit with the DOJ
OhioHealth has agreed to void problematic contracts with insurers and not seek such terms moving forward, the Justice Department said. The Ohio nonprofit continues to deny all wrongdoing.
Lifepoint taps new COO
Aaron Lewis, who has served as CFO since 2024, takes on the role as the health system looks to expand its footprint and add new services.
CBO asks for more No Surprises research
The No Surprises Act “might not have the effects that CBO anticipated,” the agency wrote in petitioning for more research into the 2020 law’s effect on healthcare prices and other trends. It’s a welcome development for payers.
Fewer insurers participating in ACA marketplaces amid policy turmoil, KFF finds
The average number of issuers fell from a record high of 9.6 per state in 2025 to just nine this year, according to the health policy research group.
CMS proposes Medicare coverage expansion for TAVR
The proposed change adds Medicare coverage for beneficiaries with asymptomatic severe aortic valve stenosis who are enrolled in a CMS-approved study.
IRhythm discloses data stolen from third-party applications in cyberattack
The cardiac monitoring company said that a threat actor has demanded payment in exchange for not publicly releasing the stolen data.
Express Scripts, PCMA sue to block Tennesee law breaking up PBMs and pharmacies
Express Scripts and the PBM lobby are following in CVS Caremark’s footsteps in filing complaints challenging the FAIR Rx Act, which was passed earlier this year despite vehement opposition from PBMs.
Centene offers employee buyouts amid membership losses
Most of Centene’s 61,000 employees will be eligible to apply for voluntary separation. But the program doesn’t amount to a complete overhaul of the company, a spokesperson said.
Medicare drug price rule may target under-the-skin cancer immunotherapies
For 2029, a federal rule proposes closing a “loophole” that protects medicines transitioning from intravenous administration from price protection.